Clinical Trials for MacroGenics

Explore 11 clinical trials worldwide

Showing 1-11 of 11 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: MacroGenics

Clinical Trials (11)

NCT07071961
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
PHASE2Not yet recruiting
16 participants
Started: Jan 1, 2026 · Completed: May 1, 2029
3 conditions3 sponsors1 location
NCT06730347
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
PHASE2Recruiting
60 participants
Started: May 1, 2025 · Completed: Aug 31, 2027
11 conditions1 sponsor16 locations
NCT06723236
A Study of MGC028 in Participants With Advanced Solid Tumors
PHASE1Recruiting
124 participants
Started: Feb 13, 2025 · Completed: Apr 30, 2027
5 conditions1 sponsor6 locations
NCT06227546
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
PHASE2Active, not recruiting
9 participants
Started: Apr 15, 2024 · Completed: May 31, 2026
1 condition2 sponsors1 location
NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
PHASE1Recruiting
250 participants
Started: Mar 6, 2024 · Completed: Oct 31, 2028
22 conditions1 sponsor11 locations
NCT06014255
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
PHASE2Recruiting
219 participants
Started: Feb 16, 2024 · Completed: Mar 1, 2029
1 condition2 sponsors5 locations
NCT05848011
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
PHASE2Active, not recruiting
154 participants
Started: Sep 28, 2023 · Completed: Sep 30, 2027
9 conditions1 sponsor51 locations
NCT05475171
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
PHASE2Recruiting
40 participants
Started: Dec 13, 2022 · Completed: Jun 30, 2026
2 conditions2 sponsors1 location
NCT05362773
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
PHASE1Recruiting
130 participants
Started: Jul 13, 2022 · Completed: May 31, 2027
8 conditions1 sponsor7 locations
NCT04425018
MARGetuximab Or Trastuzumab (MARGOT)
PHASE2Active, not recruiting
174 participants
Started: Jul 13, 2020 · Completed: Jul 1, 2027
4 conditions3 sponsors14 locations
NCT02923180
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
PHASE2Active, not recruiting
33 participants
Started: Feb 14, 2017 · Completed: Jul 31, 2026
1 condition2 sponsors1 location